The deficient expression of GPI-AP is the underlying molecular mechanism of PNH. In adults the close relationship of acquired AA and PNH is well established. The proportion of adult AA patients with a significant GPI-AP deficient population is 30-50%. Not much is known about the interrelation of AA and PNH in children. Therefore the frequency of GPI-AP deficiency at diagnosis and during the course of the disease was analyzed in the SAA 94 study. Between 11/93 and 11/2000 182 children with AA were enrolled. Overt PNH was an exclusion criterion. 56/182 pts. received primary BMT from an HLA-id. sibling. 126/182 pts. lacking an HLA-id. sibling underwent immunosuppressive treatment (IST). Survival in the BMT and IST group is 90% and 88%. The median follow up of the IST group is 51 mths. In 78/126 pts. of the IST group FACS analysis of expression of GPI-AP on erythrocytes, reticulocytes and lymphocytes, monocytes and granulocytes was performed (in 9 pts. not evaluable due to severe cytopenia). A significant GPI-deficient population in two or more cell lines could be demonstrated in 10/69 evaluable pts. GPIdeficiency in only one cell lineage (isolated deficiency on monocytes or granulocytes in most cases) could be detected in another 10 pts. In 6 pts. GPI-deficient populations occured during follow up. Four of the 10 pts. with a significant GPI-deficient population in 2 or more lineages developed clinical PNH 27, 34, 35 and 36 mths. after IST. The proportion of GPI-deficient granulocytes at diagnosis or relapse in these pts. was 3.9, 3.9, 6.7 and 12.5 %. No clinical PNH occured so far in pts. with normal GPI-expression prior to IST. 7/10 pts. with GPI-AP deficiency experienced cyclosporin A-dependent response or relapsed after IST . This study demonstrates that a PNH clone is present in a substantial proportion of children with AA. The finding that all 4 pts. who developed PNH during follow up after IST had a GPI-AP deficiency at diagnosis or relapse of AA points to a potential significance of GPI immunophenotyping in children with AA. This study also emphasizes that evaluation of prognostic markers for PNH in AA requires long observation time.
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Induction of apoptosis in malignant myeloid cell lines by antithymocyte globulin: implications for its efficacy in aplastic anaemia and myelodysplastic syndrome ?
Antilymphocyte globulin and antithymocyte globulin (ATG) has be-come the gold standard for immuno-suppressive treatment of aplastic anemia (AA). Recent studies also demonstrated efficacy of ATG in a subgroup of patients with low-risk myelodysplastic syndrome (MDS). ATG con-tains a number of different anti-body specificities. The component of ATG which is able to induce remissions in AA is still unknown. It is also unclear why polyclonal T-cell antibodies can induce remissions in a clonal, malignant stem cell disorder like MDS. In the light of the efficacy of ATG in MDS we hypothesized that ATG might have a direct apoptosis-inducing effect on myeloid cells. We analyzed various brands of ATG (Lymphoglobulin, Thymoglobulin [IMTIX SangStat], ATG-Fresenius S [Fresenius AG], Tecelac [Biotest]) on different lymphoid and in particular myeloid cell lines (Jurkat, KG-1a, K562, NB4, PBL-985, U937). Cell lines were incubated with ATG at concentrations from 1µg/ml to 1000 µg/ml for up to 10 days. Apoptosis was measured by staining with annexin-V and 7-aminoactinomycin D (7-AAD). At concentrations Ͼ= 10 µg/ml none of the tested ATG brands was able to induce apoptosis. However, at concentrations Ͼ= 100 µg/ml ATG induced apoptosis. Proportion of apoptotic cells after incubation of NB4 (KG-1a) with 100 µg/ml ATG for 7 days was 19% (50%), 30% (27%), 36% (37%) and 53% (92%) with Lymphoglobulin, Thymogloblin, ATG-Fresenius S and Tecelac, resp. Sensitivity to apoptosis induction varied between the myeloid cell lines with highest sensitivity observed in KG-1a and NB4. Significant ATG-induced apoptosis was only seen after Ͼ= 2 days of incubation and increased up to 10 days of incubation. No synergistic effects on apoptosis induction by ATG and cytostatic drugs (e.g. etoposide) could be demonstrated. Suboptimal doses of ATG and a monoclonal apoptosis-inducing FAS-antibody (DX2) had additive effects. By competitive binding studies we could not demonstrate that ATG preparations contained antibodies to the DX2-binding epitope. In summary, this study shows that ATG can induce apoptosis in myeloid cell lines. This effect of ATG might play a role for its efficacy in MDS and potentially also in AA. When using ATG in preparative regimens prior to transplant direct effects of ATG on myeloid cells should also be taken into account.
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Overexpression of myelosuppressive citokines in T-Lymphocytes of aplastic anemia patients C. Dufour, J. Svahn, A. Corcione, R. Haupt, N. Battilana, V. Pistoia (Genova, I)
The intracytoplasmic expression of γ-IFN and α-TNF in CD4+ and CD8+ cells from both peripheral blood (PB) and bone marrow (BM) from 12 pediatric patients with aplastic anaemia (7 males, 5 females, median age 8.5, range 3-22 yers) and two groups of normal controls (10 males, 5 females, median age 10, range 1-40 yrs; 8 males, 4 females, median age 12, range 6-17 yrs respectively) was studied by flow cytometry analysis. γ-IFN and α-TNF were also tested in culture supernatant from nonstimulated marrow MNCs from patients and controls. Nine patients had active disease (at onset or relapsed after previous treatment), 3 were in remission after some form of immunosuppression, 3 were on no treatment, 7 were on steroids (with the addition of G-CSF in 5 patients and of CSA in 1 case), 1 was on androgens and 1on G-GCSF alone. RESULTS i) BM CD4+ and CD8+ cells expressing both γ-IFN and α-TNF were significantly increased in the patients as compared to controls (p from Ͻ0.05 to Ͻ0.0001 in the 4 cellular subsets). ii)In the patient group BM CD4+ and CD8+ cells containing both γ-IFN and α-TNF were significantly enhanced when compared to the same cell fractions from paired PB samples (p from Ͻ0.05 to Ͻ0.001 in the various cellular subsets). iii) In the culture supernatant of patients BM MNCs, γ-IFN was detected in 4/8 cases and α-TNFin 5/8 subjects whereas neither cytokine was traceable in the controls. Amongst patients mean α-TNF values were 11.2-folds greater than those of γ-IFN. iv) The percentage of PB CD4+ and CD8+ cells expressing both γ-IFN and α-TNF were not significantly higher than those found in PB of controls. v) BM CD4+ and CD8+ cells containing α-TNF were significantly reduced in patients with favourable outcome in comprison to those with unfavourable outcome (pϽ0.01 for CD4+ and Ͻ0.05 for CD 8+). CONCLUSION Overall these findings show that in paediatric aplastic patients γ-IFN and α-TNF activities are essentially located in bone marrow rather than in peripheral blood and that intracytoplasmic expressions &#61537;-TNF in marrow T-lymphocytes may be associated with unfavourable outcome BACKGROUND: A relationship between aplastic anemia and pregnancy remains controversial. Aplastic anemia may develop during pregnancy, and sometimes recover spontaneously after delivery. The effect of pregnancy on the disease after successful treatment is poorly understood. We studied 47 pregnancies occurring after immunosuppressive treatment for aplastic anemia. PATIENTS: Twelve centers reported on 47 pregnancies in 36 females. Eight females were studied during two, and one female during four pregnancies. Outcomes of pregnancy and of aplastic anemia, as well as changes of peripheral blood counts during and after pregnancy were evaluated. RESULTS: The 47 pregnancies resulted in 43 live birth (one set of twins), one intrauterine death, two elective and two spontaneous abortions. There were 26 vaginal and 17 cesarean deliveries. Twenty one pregnancies (45%) were remarkable by presenting a complication either in the mother (n=12), the child (n=6) or both (n=3). Prematurity (n=6), spontaneous abortion (n=2), dead child (n=1) and uretheral occlusion were the remarkable events observed in the new-borns. Median birth weight was 3.3 Kg (range 1.84-4.0 Kg). Nine of the 47 (19%) pregnancies were complicated by a relapse of aplastic anemia. After delivery, 8 of the 9 relapses recovered, 5 of them spontaneously and 3 patients after re-treatment. One patient did not respond to retreatment and died one year later with aplastic anemia. In addition to the 9 patients with relapse, 4 patients needed transfusions at time of delivery. Two cases of eclampsia occurred; one in a mother with paroxysmal nocturnal hemoglobinuria (PNH), and the other in a case of relapse. Furthermore, a woman with PNH died one month after delivery from a cerebral thrombosis. As compared to pre-pregnancy values, the women showed a decrease in hemoglobin of 83% (CI 75%; 75-88%; P=0.001) in the second and of 78% (CI 75%; 68-86%; PϽ0.001) in the third trimester. The decrease of platelet counts was 66% (CI 75%; 45-95%; P=0.01) in the second, and 60% (CI 75%; 35-95%; PϾ0.001) in the third trimester. One to six months after delivery blood counts of all females with an uncomplicated pregnancy returned to pre-pregnancy values. CONCLUSIONS: Pregnancy for women in remission of aplastic anemia after immunosuppression is possible. However, there is a small but definitive risk of disease relapse and post-partum mortality, particularly in women with a clinical PNH.
